Stockscreener 앱 받기
17.45
15.41%
2.33
시간 외 거래:
17.11
-0.34
-1.95%
전일 마감가:
$15.12
열려 있는:
$18.98
하루 거래량:
451.70K
Relative Volume:
16.41
시가총액:
$131.62M
수익:
$56.54M
순이익/손실:
$-30.70M
주가수익비율:
-44.74
EPS:
-0.39
순현금흐름:
$-31.05M
1주 성능:
+20.51%
1개월 성능:
+55.53%
6개월 성능:
+64.31%
1년 성능:
+19.11%
1일 변동 폭
$17.17
$19.98
1주일 범위
$13.90
$19.98
52주 변동 폭
$10.00
$24.40
Cidara Therapeutics Inc Stock (CDTX) Company Profile
명칭
Cidara Therapeutics Inc
전화
858-752-6170
주소
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
CDTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CDTX | 17.45 | 131.62M | 56.54M | -30.70M | -31.05M | -0.39 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | 재개 | H.C. Wainwright | Buy |
| 2021-09-22 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | 개시 | Aegis Capital | Buy |
| 2019-09-04 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-07-26 | 개시 | Citigroup | Buy |
| 2017-04-21 | 개시 | Raymond James | Strong Buy |
| 2017-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Ladenburg Thalmann | Buy |
| 2017-04-11 | 재개 | Wedbush | Outperform |
| 2017-02-22 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-22 | 업그레이드 | WBB Securities | Sell → Hold |
| 2016-12-21 | 재개 | Leerink Partners | Outperform |
| 2016-12-19 | 개시 | H.C. Wainwright | Buy |
| 2016-09-23 | 다운그레이드 | WBB Securities | Hold → Sell |
| 2015-10-09 | 업그레이드 | WBB Securities | Sell → Hold |
| 2015-05-11 | 개시 | Jefferies | Buy |
| 2015-05-11 | 개시 | Leerink Partners | Outperform |
| 2015-05-11 | 개시 | Needham | Buy |
| 2015-05-11 | 개시 | Wedbush | Outperform |
| 2015-04-23 | 개시 | WBB Securities | Sell |
모두보기
Cidara Therapeutics Inc 주식(CDTX)의 최신 뉴스
Cidara: Potential To Change Flu Prophylaxis Landscape With CD388 - Seeking Alpha
Cidara to raise up to $105 million in private placement - The Pharma Letter
Cidara Therapeutics Shares Surge 26% on $105 Mln Private Placement - MarketWatch
Cidara Therapeutics announces $105 million private placement - Investing.com
Cidara Therapeutics Announces $105 Million Private Placement - GlobeNewswire
Cidara Therapeutics Secures $105M Private Placement Led by Venrock Healthcare | CDTX Stock News - StockTitan
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference - GlobeNewswire
Cidara Therapeutics CEO to Present at Evercore HealthCONx Conference | CDTX Stock News - StockTitan
(CDTX) Technical Data - Stock Traders Daily
HC Wainwright Has Positive Outlook of CDTX FY2024 Earnings - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at HC Wainwright - MarketBeat
Analysts Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $29.67 - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Guggenheim - MarketBeat
Cidara Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cidara's Q3 Loss Widens to $16M Despite Strong CD388 Trial Progress and Cash Position | CDTX Stock News - StockTitan
(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire
How Cidara Got Its Molecule Back - BioProcess Online
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat
Cidara Therapeutics, Inc. (CDTX) Stock Price & Chart | Trade Now - Capital.com
Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire
(CDTX) Investment Analysis and Advice - Stock Traders Daily
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com
(CDTX) On The My Stocks Page - Stock Traders Daily
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology
Cidara Therapeutics Announces Two Presentations on - GlobeNewswire
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan
How to Take Advantage of moves in (CDTX) - Stock Traders Daily
Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations
Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada
Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World
Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch
Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Cidara starts Phase 2b trial of influenza drug CD388 - Investing.com
Cidara Therapeutics Announces First Subjects Dosed in Phase - GlobeNewswire
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - StockTitan
Biotechs investigate ways to adapt to new clinical trial regulation and economic flux - Yahoo Finance
Cidara Therapeutics expands Scientific Advisory Board By Investing.com - Investing.com Canada
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
Cidara Therapeutics Inc (CDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):